Leerink Partners Initiates Kazia Therapeutics Coverage With Outperform Rating
Leerink Partners initiated coverage with an Outperform rating and a $30 price target. The target implies 282.2% upside from the Oct. 19 close of $7.85.
Leerink Partners initiated coverage with an Outperform rating and a $30 price target. The target implies 282.2% upside from the Oct. 19 close of $7.85.